MY207220A - Anti-hemagglutinin antibodies and methods of use thereof - Google Patents

Anti-hemagglutinin antibodies and methods of use thereof

Info

Publication number
MY207220A
MY207220A MYPI2022002059A MYPI2022002059A MY207220A MY 207220 A MY207220 A MY 207220A MY PI2022002059 A MYPI2022002059 A MY PI2022002059A MY PI2022002059 A MYPI2022002059 A MY PI2022002059A MY 207220 A MY207220 A MY 207220A
Authority
MY
Malaysia
Prior art keywords
antibodies
influenza
methods
bind
preventing
Prior art date
Application number
MYPI2022002059A
Other languages
English (en)
Inventor
Christos Kyratsous
Alina Baum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY207220A publication Critical patent/MY207220A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
MYPI2022002059A 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof MY207220A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US202063094170P 2020-10-20 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MY207220A true MY207220A (en) 2025-02-06

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022002059A MY207220A (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Country Status (14)

Country Link
US (2) US11773156B2 (enExample)
EP (1) EP4051707A1 (enExample)
JP (1) JP7611908B2 (enExample)
KR (1) KR20220088446A (enExample)
CN (1) CN114761428A (enExample)
AU (2) AU2020374878B2 (enExample)
BR (1) BR112022007923A2 (enExample)
CA (1) CA3153944A1 (enExample)
CL (1) CL2022001067A1 (enExample)
CO (1) CO2022005281A2 (enExample)
IL (1) IL292353A (enExample)
MY (1) MY207220A (enExample)
PH (1) PH12022550963A1 (enExample)
WO (1) WO2021086899A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EP2814841A4 (en) * 2012-01-31 2015-06-17 Univ Osaka HUMAN MONOCLONAL ANTIBODIES FOR WIDE PROTECTION AGAINST INFLUENZA B VIRUS AND METHOD OF USE THEREOF
EP2825036B1 (en) * 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) * 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
TW201620932A (zh) * 2014-03-27 2016-06-16 建南德克公司 抗－ｂ型流感病毒血球凝集素抗體及其使用方法
MX392761B (es) * 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
HUE056407T2 (hu) * 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
CN106243218B (zh) 2015-06-03 2020-05-15 厦门大学 抗Flu B的广谱单克隆抗体及其用途
MX2018015755A (es) * 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) * 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11780907B2 (en) * 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin

Also Published As

Publication number Publication date
CO2022005281A2 (es) 2022-05-10
AU2020374878B2 (en) 2025-10-16
US11773156B2 (en) 2023-10-03
US20210171612A1 (en) 2021-06-10
IL292353A (en) 2022-06-01
US20240083983A1 (en) 2024-03-14
CA3153944A1 (en) 2021-05-06
JP2022553703A (ja) 2022-12-26
JP7611908B2 (ja) 2025-01-10
CL2022001067A1 (es) 2023-01-27
AU2020374878A1 (en) 2022-04-28
WO2021086899A1 (en) 2021-05-06
KR20220088446A (ko) 2022-06-27
EP4051707A1 (en) 2022-09-07
CN114761428A (zh) 2022-07-15
BR112022007923A2 (pt) 2022-07-26
PH12022550963A1 (en) 2023-09-25
AU2025271140A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
EP4653051A3 (en) Human antibodies to ebola virus glycoprotein
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
MY207220A (en) Anti-hemagglutinin antibodies and methods of use thereof
WO2014160171A3 (en) Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
HK1240605A1 (zh) 针对埃博拉病毒糖蛋白的人抗体
EA202191973A3 (ru) Человеческие антитела к гликопротеину вируса эбола
MA40375B1 (fr) Anticorps humains contre l'hémagglutinine de la grippe